Discov Oncol. 2025 Dec 14. doi: 10.1007/s12672-025-04287-0. Online ahead of print.
ABSTRACT
PURPOSE: To evaluate the clinicopathological characteristics of breast invasive micropapillary carcinoma (IMPC) and identify factors associated with recurrence and metastasis.
METHODS: The study retrospectively analyzed 401 cases of breast IMPC diagnosed between 2017 and 2021. The primary endpoint was recurrence and metastasis-free survival (RMFS). Secondary endpoints included locoregional recurrence-free survival (LRRFS) and distant metastasis-free survival (DMFS). Survival was estimated using the Kaplan-Meier method and compared with the log-rank test. Univariable and multivariable Cox regression analyses were performed to identify prognostic factors. Continuous variables were categorized using maximum log-rank statistics to optimize group stratification.
RESULTS: The median follow-up duration was 46.9 months (range, 1-92 months). The 5-year RMFS, LRRFS and DMFS rates were 86.0% (95% CI, 82.2%-90.0%), 97.5% (95% CI, 95.8%-99.3%) and 86.5% (95% CI, 82.8%-90.5%), respectively. Multivariable Cox analysis showed that maximum tumor diameter (≤ 1.7 cm vs. >1.7 cm, P = 0.018), the log odds of positive lymph nodes (LODDS) (≤ 0 vs. >0, P = 0.008), histological grade (I-II vs. III, P = 0.002), and receipt of neoadjuvant chemotherapy (P = 0.003) were independent predictors of recurrence and metastasis.
CONCLUSION: Breast IMPC carries a relatively high risk of recurrence and metastasis. Tumor size, LODDS, histologic grade, and neoadjuvant chemotherapy were independently associated with outcomes, underscoring the need for closer clinical monitoring and refined risk stratification in this subtype.
PMID:41391067 | DOI:10.1007/s12672-025-04287-0
